Stock PHRM PHARMATHER HOLDINGS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News PharmaTher Holdings Ltd.

Equities

PHRM

CA71716H1082

Market Closed - Canadian Securities Exchange
Other stock markets
 02:50:18 2024-07-12 pm EDT 		5-day change 1st Jan Change
0.225 CAD +2.27% Intraday chart for PharmaTher Holdings Ltd. +4.65% -28.57%
May. 15 PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine MT
May. 10 PharmaTher Assigned FDA Approval Goal Date for its New Drug Application for Ketamine MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
PharmaTher's Sairiyo Submits Clinical Trial Application in Australia For Phase 1 Study of Reformulated Cepharanthine
MT
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
GL
PharmaTher Assigned FDA Approval Goal Date for its New Drug Application for Ketamine
MT
PharmaTher Brief: Announcing Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
MT
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
GL
PharmaTher Holdings Ltd. Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
CI
PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia
MT
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
GL
PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024
CI
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
GL
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine
MT
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
GL
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine
CI
PharmaTher Provides Update For PD-001
MT
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
GL
CapitalGainsReport: Foreign Stocks Under .2 With Growing Potential (TBRIF, BRHCF, FFNTF, PHRRF)
AQ
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine
MT
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
GL
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
AQ
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHRM Stock
  4. News PharmaTher Holdings Ltd.